| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T18 |
3-7 |
NNP |
denotes |
East |
| T19 |
8-19 |
JJ |
denotes |
respiratory |
| T20 |
20-28 |
NN |
denotes |
syndrome |
| T21 |
29-30 |
-LRB- |
denotes |
( |
| T22 |
30-34 |
NNS |
denotes |
MERS |
| T23 |
34-35 |
-RRB- |
denotes |
) |
| T24 |
36-49 |
NNS |
denotes |
coronaviruses |
| T25 |
50-51 |
-LRB- |
denotes |
( |
| T26 |
51-55 |
NNS |
denotes |
CoVs |
| T27 |
55-56 |
-RRB- |
denotes |
) |
| T28 |
57-60 |
VBP |
denotes |
are |
| T29 |
61-69 |
JJ |
denotes |
zoonotic |
| T30 |
70-79 |
NNS |
denotes |
pathogens |
| T31 |
80-84 |
IN |
denotes |
with |
| T32 |
85-89 |
JJ |
denotes |
high |
| T33 |
90-98 |
NN |
denotes |
fatality |
| T34 |
99-104 |
NNS |
denotes |
rates |
| T35 |
105-108 |
CC |
denotes |
and |
| T36 |
109-117 |
JJ |
denotes |
pandemic |
| T37 |
118-127 |
NN |
denotes |
potential |
| T38 |
129-136 |
NN |
denotes |
Vaccine |
| T39 |
137-148 |
NN |
denotes |
development |
| T40 |
149-156 |
VBZ |
denotes |
focuses |
| T41 |
157-159 |
IN |
denotes |
on |
| T42 |
160-163 |
DT |
denotes |
the |
| T43 |
164-173 |
JJ |
denotes |
principal |
| T44 |
174-180 |
NN |
denotes |
target |
| T45 |
181-183 |
IN |
denotes |
of |
| T46 |
184-187 |
DT |
denotes |
the |
| T47 |
188-200 |
VBG |
denotes |
neutralizing |
| T48 |
201-208 |
JJ |
denotes |
humoral |
| T49 |
209-215 |
JJ |
denotes |
immune |
| T50 |
216-224 |
NN |
denotes |
response |
| T51 |
224-225 |
-COMMA- |
denotes |
, |
| T52 |
226-229 |
DT |
denotes |
the |
| T53 |
230-235 |
NN |
denotes |
spike |
| T54 |
236-237 |
-LRB- |
denotes |
( |
| T55 |
237-238 |
NN |
denotes |
S |
| T56 |
238-239 |
-RRB- |
denotes |
) |
| T57 |
240-252 |
NN |
denotes |
glycoprotein |
| T58 |
254-265 |
NN |
denotes |
Coronavirus |
| R16 |
T20 |
T18 |
arg1Of |
syndrome,East |
| R17 |
T20 |
T19 |
arg1Of |
syndrome,respiratory |
| R18 |
T20 |
T21 |
arg1Of |
syndrome,( |
| R19 |
T22 |
T21 |
arg2Of |
MERS,( |
| R20 |
T23 |
T21 |
arg3Of |
),( |
| R21 |
T28 |
T24 |
arg1Of |
are,coronaviruses |
| R22 |
T24 |
T25 |
arg1Of |
coronaviruses,( |
| R23 |
T26 |
T25 |
arg2Of |
CoVs,( |
| R24 |
T27 |
T25 |
arg3Of |
),( |
| R26 |
T30 |
T28 |
arg2Of |
pathogens,are |
| R27 |
T30 |
T29 |
arg1Of |
pathogens,zoonotic |
| R28 |
T30 |
T31 |
arg1Of |
pathogens,with |
| R29 |
T35 |
T31 |
arg2Of |
and,with |
| R30 |
T34 |
T32 |
arg1Of |
rates,high |
| R31 |
T34 |
T33 |
arg1Of |
rates,fatality |
| R32 |
T34 |
T35 |
arg1Of |
rates,and |
| R33 |
T37 |
T35 |
arg2Of |
potential,and |
| R34 |
T37 |
T36 |
arg1Of |
potential,pandemic |
| R35 |
T39 |
T38 |
arg1Of |
development,Vaccine |
| R36 |
T39 |
T40 |
arg1Of |
development,focuses |
| R37 |
T40 |
T41 |
arg1Of |
focuses,on |
| R38 |
T44 |
T41 |
arg2Of |
target,on |
| R39 |
T44 |
T42 |
arg1Of |
target,the |
| R40 |
T44 |
T43 |
arg1Of |
target,principal |
| R41 |
T44 |
T45 |
arg1Of |
target,of |
| R42 |
T50 |
T45 |
arg2Of |
response,of |
| R43 |
T50 |
T46 |
arg1Of |
response,the |
| R44 |
T50 |
T47 |
arg1Of |
response,neutralizing |
| R45 |
T50 |
T48 |
arg1Of |
response,humoral |
| R46 |
T50 |
T49 |
arg1Of |
response,immune |
| R47 |
T50 |
T51 |
arg1Of |
response,"," |
| R48 |
T57 |
T51 |
arg2Of |
glycoprotein,"," |
| R49 |
T57 |
T52 |
arg1Of |
glycoprotein,the |
| R50 |
T57 |
T53 |
arg1Of |
glycoprotein,spike |
| R51 |
T53 |
T54 |
arg1Of |
spike,( |
| R52 |
T55 |
T54 |
arg2Of |
S,( |
| R53 |
T56 |
T54 |
arg3Of |
),( |
